2. Kleiman N.S., White H.D., Ohman E.M., Ross A.M., Woodlief L.H., Califf R.M., et al. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation 1994;90:2658—65.

3. Cragg D.R., Friedman H.Z., Bonema J.D., Jaiyesimi I.S., Ramos R.G., Timmis G.C., et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991;115:173—7.

4. Althouse R., Maynard C., Cerqueira M.D., Olsufka M., Ritchie J.L., Kennedy J.W. The Western Washington Myocardial Infarction Registry and Emergency Department Tissue Plasminogen Activator Treatment Trial. Am J Cardiol 1990;66:1298—303.

5. Low K.G., Joliceour M.R., Colman R.A., Stone L.E., Fleisher C.L. Women participants in research: assessing progress. Women Health 1994;22:79—98.

6. Gurwitz J.H., Gore J.M., Goldberg R.J., Rubison M., Chandra N., Rogers W.J. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. National Registry of Myocardial Infarction. Ann Intern Med 1996;124:283—91.

7. Shaw L.J., Peterson E.D., Kesler K., Hasselblad V., Califf R.M. A meta-analysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. Am J Cardiol 1996;78:1327—37.

8. Roubin G.S., Califf R.M., O'Neill W.W., Phillips H.R. 3d, Stack R.S., eds. Interventional Cardiovascular Medicine: Principles and Practice. New York: Churchill Livingstone; 1994.

9. Braunwald E., ed. Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders; 1992.

10. Califf R.M., Mark D.B., Wagner G.S., eds. Acute Coronary Care. 2d ed. St. Louis, МО: Mosby-Year Book; 1995.

11. Eddy D.M., Hasselblad V., Shachter R. An introduction to a Bayesian method for meta-analysis: the confidence profile method. Med Decis Making 1990;10:15—23.

12. Morris R.M., Barnaby P.F., Brandt P.W., Geary G.G., Whitlock R.M., Wild C.J., et al. Prognosis after recovery from first acute myocardial infarction: determinants of reinfarction and sudden death. Am J Cardiol 1984;53:408—13.

13. Henning H., Gilpin E.A., Covell J.W., Swan E.A., O'Rourke R.A., Ross J. Jr. Prognosis after acute myocardial infarction: a multivariate analysis of mortality and survival. Circulation 1979;59:1124—36.

14. Dubois С., Pierard L.A., Albert A., Smeets J.P., Demoulin J.C., Boland J., et al. Short-term risk stratification at admission based on simple clinical data in acute myocardial infarction. Am J Cardiol 1988;61:216—9.

15. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. JAMA 1988;260:2849—58.

16. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group. Lancet 1990;336:71—5.

17. Lee K.L., Woodlief L.H., Topol E.J., Weaver W.D., Betriu A., Col J., et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-1 Investigators. Circulation 1995;91:1659—68.

18. Norris R.M., Brandt P.W., Caughey D.E., Lee A.J., Scott P.J. A new coronary prognostic index. Lancet 1969;1:274—8.

19. Fallen E.L., Armstrong P., Cairns J., Dafoe W., Frasure-Smith N., Langer A., et al. Report of the Canadian Cardiovascular Society's consensus conference on Management of the Postmyocardial Infarction Patient. Can Med Assoc J 1991;144:1015—25.

20. Madsen Е.В., Gilpin E., Henning H. Short-term prognosis in acute myocardial infarction: evaluation of different prediction methods. Am Heart J 1984;107:1241—51.

21. Mukharji J., Rude R.E., Poole W.K., Gustafson N., Thomas L.J. Jr., Strauss H.W., et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984;54:31—6.

22. Selker H.P., Griffith J.L., D'Agostino R.B. A time-insensitive predictive instrument for acute myocardial infarction mortality: a multicenter study. Med Care 1991;29:1196—211.

23. White H.D., Barbash G.I., Califf R.M., Simes R.J., Granger C.B., Weaver W.D., et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial. Circulation 1996;94:1826—33.

24. Goldberg R.J., Gore J.M., Gurwitz J.H., Alpert J.S., Brady P. Strohsnitter W., et al. The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J 1989; 117:543—9.

25. Weaver W.D., White H.D., Wilcox R.G., Aylward P.E., Morris D., Guerci A., et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I Investigators. JAMA 1996;275:777—82.

26. Vaccarino V., Krumholz H.M., Berkman L.F., Horwitz R.I. Sex differences in mortality after myocardial infarction. Is there evidence for an increased risk for women? Circulation 1995;91: 1861—71.

27. Fiebach N.H., Viscoli C.M., Horwitz R.I. Differences between women and men in survival after myocardial infarction. Biology or methodology? JAMA 1990;263:1092—6.

28. Dittrich H., Gilpin E., Nicod P., Cali G., Henning H., Ross J. Jr. Acute myocardial infarction in women: influence of gender on mortality and prognostic variables. Am J Cardiol 1988;62:1—7.

29. Lincoff A.M., Califf R.M., Ellis S.G., Sigmon K.N., Lee K.L., Topol E.J. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. J Am Coll Cardiol 1993;22:1780—7.

30. Becker R.C., Terrin M., Ross R., Knatterud G.L., Desvigne-Nickens P., Gore J.M., et al. Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. Ann Intern Med 1994;120:638—45.

31. Tofler G.H., Stone P.H., Muller J.E., Willich S.N., Davis V.G., Poole W.K., et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol 1987;9:473—82.

32. Greenland P., Reicher-Reiss H., Goldbourt U., Behar S. In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. Circulation 1991; 83: 484—91.

33. Barbash G.I., Reiner J., White H.D., Wilcox R.G., Armstrong P.W., Sadowski Z., et al. Evaluation of the paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995;26:1222—9.

34. Grines C.L., Topol E.J., O'Neill W.W., George B.S., Kereiakes D., Phillips H.R., et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 1995;91:298—303.

35. Forrester J.S., Diamond G., Chatterjee K., Swan H.J. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976;295:1356—62.

36. Killip T. 3d, Kimball J.T. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967;20:457—64.

37. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'infarto Mio-cardico (GISSI). Lancet 1986;1:397—402.

38. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989;320:618—27.

39. Zabel K.M., Hathaway W.R., Peterson E.D., Granger C.B., Armstrong P.W., Morris D., et al. Baseline electrocardiogram predicts 30-day mortality among 32,812 patients with acute myocardial infarction treated with thrombolysis [Abstract]. J Am Coll Cardiol 1995;25:342A.

40. Bilbao F.J., Zabalza I.E., Vilanova J.R., Froufe J. Atrioventricular block in posterior acute myocardial infarction: a clinicopathologic correlation. Circulation 1987;75:733—6.

41. Clemmensen P., Ohman E.M., Sevilla D.C., Peck S., Wagner N.B., Quigley P.S., et al. Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction. Am J Cardiol 1990;66:1407—11.

42. Fisch G.R., Zipes D.P., Fisch C. Bundle branch block and sudden death. Prog Cardiovasc Dis 1980;23:187—224.

43. Mavric Z., Zaputovic L., Matana A., Kucic J., Roje J., Marinovic D., et al. Prognostic significance of complete atrioventricular block in patients with acute inferior myocardial infarction with and without right ventricular involvement. Am Heart J 1990;119:823—8.

44. Goldberg R.J., Seeley D., Becker R.C., Brady P., Chen Z.Y., Osganian V. et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990;119:996—1001.

45. Bates E.R., Clemmensen P.M., Califf R.M., German L.E., Aronson L.G., George B.S., et al. Precordial ST segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1990;16:1538—44.

46. Lembo N.J., Starling M.R., Dell'ltalia L.J., Crawford M.H., Chaudhuri T.K., O'Rourke R.A. Clinical and prognostic importance of persistent precordial (V1-V4) electrocardiographic ST segment depression in patients with inferior transmural myocardial infarction. Circulation 1986;74:56—63.

47. Peterson E.D., Hathaway W.R., Zabel K.M., Pieper K.S., Granger C.B., Wagner G.S., et al. Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. J Am Coll Cardiol 1996;28:305—12.

48. Zehender M., Kasper W., Kauder E., Schonthaler M., Geibel A., Olschewski M., et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993;218:981—8.

49. Lee T.H., Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction. Recommendations based on a quantitative analysis. Ann Intern Med 1986;105:221—33.

50. Lee T.H., Weisberg M.C., Cook E.F., Daley K., Brand D.A., Goldman L. Evaluation of creatine kinase and creatine kinase-MB for diagnosing myocardial infarction. Clinical impact in the emergency room. Arch Intern Med 1987;147:115—21.

51. Katus Н.А., Remppis A., Scheffold T., Diederich K.W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991;67: 1360—7.

52. Adams J.E. 3d, Bodor G.S., Davila-Roman V.G., Delmez J.A., Apple F.S., Ladenson J.H., et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88: 101—6.

53. Wagner I., Mair J., Fridrich L., Artner-Dworzak E., Lechleitner P., Morass B., et al. Cardiac troponin T release in acute myocardial infarction is associated with scintigraphic estimates of myocardial scar. Coron Artery Dis 1993;4:537—44.

54. Ohman Е.М., Armstrong P.W., Christenson R.H., Granger C.B., Katus H.A., Hamm C.W., et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333—41.

55. Remppis A., Scheffold T., Karrer 0., Zehelein J., Hamm C., Grunig E., et al. Assessment of reperfusion of the infarct zone after acute myocardial infarction by serial cardiac troponin T measurements in serum. Br Heart J 1994;71:242—8.

56. Abe S., Arima S., Yamashita T., Miyata M., Okino H., Toda H., et al. Early assessment of reperfusion therapy using cardiac troponin T. J Am Coll Cardiol 1994;23:1382—9.

57. Pellikka P.A., Behrenbeck T., Verani M.S., Mahmarian J.J., Wackers F.J., Gibbons R.J. Serial changes in myocardial perfusion using tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging following reperfusion therapy of myocardial infarction. J Nucl Med 1990;31:1269—75.

58. Wackers F.J., Terrin M.L., Kayden D.S., Knatterud G., Forman S., Braunwald E., et al. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. J Am Coll Cardiol 1989;13:998—1005.

59. McCallister B.D. Jr., Christian T.F., Gersh B.J., Gibbons R.J. Prognosis of myocardial infarctions involving more than 40% of the left ventricle after acute reperfusion therapy. Circulation 1993;88(4 Pt 1):1470—5.

60. Gibbons R.J., Verani M.S., Behrenbeck T., Pellikka P.A., O'Connor M.K., Mahmarian J.J., et al. Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation 1989;80:1277—86.

61. Christian T.F., Schwartz R.S., Gibbons R.J. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation 1992;86:81—90.

62. Lomboy C.T., Schulman D.S., Grill H.P., Flores A.R., Orie J.E., Granato J.E. Rest-redistribution thallium-201 scintigraphy to determine myocardial viability early after myocardial infarction. J Am Coll Cardiol 1995;25:210—7.

63. Cornel J.H., Arnese M., Forster T., Postma-Tjoa J., Reijs A.E., Fioretti P.M. Potential and limitations of Tc-99m sestamibi scintigraphy for the diagnosis of myocardial viability. Herz 1994;19:19—27.

64. Corbett J.R., Lewis S.E., Wolfe C.L., Jansen D.E., Lewis M., Rellas J.S., et al. Measurement of myocardial infarct size by technetium pyrophosphate single-photon tomography. Am J Cardiol 1984;54:1231—6.

65. Tamaki S., Kadota К., Kambara H., Suzuki Y., Nohara R., Murakami T., et al. Emission computed tomography with technetium-99m pyrophosphate for delineating location and size of acute myocardial infarction in man. Br Heart J 1984;52:30—7.

66. Huber К.С., Bresnahan J.F., Bresnahan D.R., Pellikka P.A., Behrenbeck T., Gibbons R.J. Measurement of myocardium at risk by technetium-99m sestamibi: correlation with coronary angiography. J Am Coll Cardiol 1992;19: 67—73.

67. De Coster P.M., Wijns W., Cauwe F., Robert A., Beckers C., Melin J.A. Area-at-risk determination by technetium-99m-hexakis-2-methoxyisobutyl isonitrile in experimental reperfused myocardial infarction. Circulation 1990; 82:2152—62.

68. Macieira-Coelho E., Cantinho G., da Costa B.B., Garcia-Alves M., Lacerda A.P., Dionisio I., et al. Minimal residual coronary obstructions in patients who suffered a first myocardial infarction. A prospective study comparing coronary angiography and exercise thallium scintigraphy. Clin Cardiol 1993; 16:879—82.

69. Fletcher W.O., Gibbons R.J., Clements I.P. The relationship of inferior ST depression, lateral ST elevation, and left precordial ST elevation to myocardium at risk in acute anterior myocardial infarction. Am Heart J 1993;126(3 Pt 1):526—35.

70. Christian T.F., Clements I.P., Behrenbeck T., Huber К.С., Chesebro J.H., Gersh B.J., et al. Limitations of the electrocardiogram in estimating infarction size after acute reperfusion therapy for myocardial infarction. Ann Intern Med 1991;114:264—70.

71. Silverman K.J., Becker L.C., Bulkley B.H., Burow R.D., Mellits E.D., Kallman C.H., et al. Value of early thallium-201 scintigraphy for predicting mortality in patients with acute myocardial infarction. Circulation 1980;61:996—1003.

72. Gibson W.S., Christian T.F., Pellikka P.A., Behrenbeck T., Gibbons R.J. Serial tomographic imaging with technetium-99m-sestamibi for the assessment of infarct-related arterial patency following reperfusion therapy. J Nucl Med 1992;33:2080—5.

73. Cerqueira M.D., Maynard C., Ritchie J.L., Davis K.B., Kennedy J.W. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials. J Am Coll Cardiol 1992;20:1452—9.

74. Niemeyer M.G., Van der Wall Е.Е., Pauwels E.K., van Dijkman P.R., Blokland J.A., de Roos A., et al. Assessment of acute myocardial infarction by nuclear imaging techniques. Angiology 1992;43:720—33.

75. Shimada T., Tsuda N., Karnihata H., Suga Y., Kurimoto T., Iwasaka T., et al. Quantification of infarct size by thallium-201 single-photon emission computed tomography using the unfolded map method. Comparison with QRS score and angiographic infarct size at 4 weeks after infarction. Clin Cardiol 1994;17:184—90.

76. Howarth D., Coote D. "Window on the heart" technique for diagnosis of recent myocardial infarction using Tc-99m pyrophosphate SPECT subtraction imaging. Clin Nucl Med 1995;20:1—4.

77. Bostrom P.A., Diemer H., Freitag M., Juhlin P., Lilja B., Erhardt L. Myocardial reperfusion in thrombolysis A 99Tcm-Sestamibi SPECT study in patients with acute myocardial infarction. Clin Physiol 1992;12:679—84.

78. Walamies M., Virtanen V., Koskinen M., Uusitalo A. Patency of the infarct-related coronary artery—a pertinent factor in late recovery of myocardial fatty acid metabolism among patients receiving thrombolytic therapy? Eur J Nucl Med 1994;21:968—72.

79. Sridhara B.S., Dudzic E., Basu S., Senior R., Lahiri A. Reverse redistribution of thallium-201 represents a low-risk finding in thrombolysed patients following myocardial infarction. Eur J Nucl Med 1994;21:1094—7.

80. Christian T.F., Clements I.P., Gibbons R.J. Noninvasive identification of myocardium at risk in patients with acute myocardial infarction and nondiagnostic electrocardiograms with technetium-99m-sestamibi. Circulation 1991;83:1615—20.

81. St. John Sutton M., Pfeffer M.A., Plappert T. Rouleau J.L., Moye L.A., Dagenais G.R., et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89:68—75.

82. Sabia P., Abbott R.D., Afrookteh A., Keller M.W. Touchstone D.A., Kaul S. Importance of two-dimensional echocardiographic assessment of left ventricular systolic function in patients presenting to the emergency room with cardiac-related symptoms. Circulation 1991;84:1615—24.

83. Nishimura R.A., Tajik A.J., Shub C., Miller F.A. Jr., Ilstrup D.M., Harrison C.E. Role of two-dimensional echocardiography in the prediction of in-hospital complications after acute myocardial infarction. J Am Coll Cardiol 1984;4:1080—7.

84. Berning J., Launbjerg J., Appleyard M. Echocardiographic algorithms for admission and predischarge prediction of mortality in acute myocardial infarction. Am J Cardiol 1992;69:1538—44.

85. Kan G., Visser C.A., Koolen J.J., Dunning A.J. Short and long term predictive value of admission wall motion score in acute myocardial infarction. A cross sectional echocardiographic study of 345 patients. Br Heart J 1986;56:422—7.

86. Fleischmann K.E., Goldman L., Robiolio P.A., Lee R.T., Johnson P.A., Cook E.F., et al. Echocardiographic correlates of survival in patients with chest pain. J Am Coll Cardiol 1994;23:1390—6.

87. Bengtson J.R., Kaplan A.J., Pieper K.S., Wildermann N.M., Mark D.B., Pryor D.B., et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992;20:1482—9.

88. Califf R.M., Bengtson J.R. Cardiogenic shock. N Engl J Med 1994;330:1724—30.

89. Binder M.J., Ryan J.A., Marcus S., Mugler F., Strange D., Agress C.M. Evaluation of therapy in shock following acute myocardial infarction. Am J Med 1985;8:622—32.

90. Hands M.E., Rutherford J.D., Muller J.E., Davies G., Stone P.H., Parker C., et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol 1989;14:40—6.

91. Rackley C.E., Russell R.O. Jr., Mantle J.A., Rogers W.J. Cardiogenic shock. Cardiovasc Clin 1981;11:15—24.

92. Scheidt S., Ascheim R., Killip T. 3d. Shock after acute myocardial infarction. A clinical and hemodynamic profile. Am J Cardiol 1970;26:556—64.

93. Swan H.J., Forrester J.S., Danzig R., Alien H.N. Power failure in acute myocardial infarction. Prog Cardiovasc Dis 1970; 12: 568—600.

94. Robin E.D. The cult of the Swan-Ganz catheter. Overuse and abuse of pulmonary flow catheters. Ann Intern Med 1985;103: 445—9.

95. Eisenberg P.R., Jaffe A.S., Schuster D.P. Clinical evaluation compared to pulmonary artery catheterization in the hemodynamic assessment of critically ill patients. Crit Care Med 1984;12:549—53.

96. Connors A.F., Speroff T., Dawson N.V., Thomas C., Harrell F.E., Wagner D., et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996;276:889—97.

97. Waksman R., Weiss A.T., Gotsman M.S., Hasin Y. Intra-aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. Eur Heart J 1993;14:71—4.

98. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311—22.

99. Bates E.R., Topol E.J. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991;18:1077—84.

100. Meyer J., Merx W., Dorr R., Lambertz H., Bethge C., Effert S. Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). Am Heart J 1982;103:132—4.

101. Holmes D.R. Jr., Bates E.R., Kleiman N.S., Sadowski Z., Horgan J.H., Morris D.C., et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995;26:668—74.

102. Lee L., Bates E.R., Pitt B., Walton J.A., Laufer N., O'Neill W.W. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345—51.

103. Sotolongo R.P., Smith M.L., Margolis W.S. Coronary angioplasty in emergency treatment of myocardial infarction. Тех Heart Inst J 1990;17:31—6.

104. O'Neill W.W. Angioplasty therapy of cardiogenic shock: are randomized trials necessary? [Editorial] J Am Coll Cardiol 1992;19:915—7.

105. Wall T.C., Ohman Е.М., Califf R.M. Reperfusion therapy: significance of recent trials to the practicing cardiologist. In: Anderson J.L., ed. Modern Management of Acute Myocardial Infarction in the Community Hospital. New York: Marcel Dekker; 1991;103—18.

106. Stone G.W., Grines C.L., Browne K.F., Marco J., Rothbaum D., O'Keefe J., et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995;25:370—7.

107. de Boer M.J., Suryapranata H., Hoorntje J.C., Reiffers S., Liem A.L., Miedema K., et al. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction. Circulation 1994;90:753—61.

108. Gibbons R.J., Holmes D.R., Reeder G.S., Bailey K.R., Hopfenspirger M.R., Gersh B.J. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med 1993;328:685—91.

109. Ferguson J.J. American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation 1996;94:1—5.

110. Brott T., Thalinger K., Hertzberg V. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke 1986;17:1078—83.

111. Krumholz H.M. The clinical challenges of myocardial infarction in the elderly. West J Med 1989;151:304—10.

112. Grines C.L. Selection of patients for reperfusion therapy. In: Califf R.M., Mark D.B., Wagner G.S., eds. Acute Coronary Care. 2d ed. St. Louis, МО: Mosby; 1995;215—28.

113. Bates E.R. Reperfusion therapy in inferior myocardial infarction. J Am Coll Cardiol 1988;12:44A-51A.

114. Grines C.L., DeMaria A.N. Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies. J Am Coll Cardiol 1990;16:223—31.

115. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996;335:775—82.

116. Antman Е.М. Hirudin in acute myocardial infarction—thrombolysis and thrombin in myocardial infarction (TIMI) 9В trial. Circulation 1996;94:911—21.

117. Braunwald E., Mark D.B., Jones R.H., Cheitlin M.D., Fuster V., McCauley K.M., et al. Unstable Angina: Diagnosis and Management. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, National Heart, Lung, and Blood Institute;1994:1—154.

118. Lown В., Fakho A.M., Hood W.B. Jr., Thorn G.W. The coronary care unit. New perspectives and directions. JAMA 1967;199:188—98.

119. Goldman L. Coronary care units. A perspective on their epidemiologic impact. Int J Cardiol 1982;2:284—7.

120. Lee T.H., Juarez G., Cook E.F., Weisberg M.C., Rouan G.W., Brand D.A., et al. Ruling out acute myocardial infarction. A prospective multicenter validation of a 12-hour strategy for patients at low risk. N Engl J Med 1991;324:1239—46.

121. Gibler W.B., Runyon J.P., Levy R.C., Sayre M.R., Kacich R., Hattemer C.R., et al. A rapid diagnostic and treatment center for patients with chest pain in the emergency department. Ann Emerg Med 1995;25:1—8.

122. Gaspoz J.M., Lee T.H., Weinstein M.C., Cook E.F., Goldman P., Komaroff A.L., et al. Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients. J Am Coll Cardiol 1994;24:1249—59.

123. Barbagelata A., Granger C.B., Topol E.J., Worley S.J., Kereiakes D.J., George B.S., et al. Isolated recurrent ischemia after thrombolytic therapy: incidence, importance, and cost. Am J Cardiol 1995;76:1007—13.

124. Betriu A., Heras M., Cohen M., Fuster V. Unstable angina: outcome according to clinical presentation. J Am Coll Cardiol 1992;19:1659—63.

125. Ohman Е.М., Topol E.J., Califf R.M., Bates E.R., Ellis S.G., Kereiakes D.J., et al. An analysis of the cause of early mortality after administration of thrombolytic therapy. The Thrombolysis Angioplasty in Myocardial Infarction Study Group. Coron Artery Dis 1993;4:957—64.

126. Roberts R., Rogers W.J., Mueller H.S., Lambrew C.T., Diver D.J., Smith H.C., et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83:422—37.

127. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993;329: 1615—22.

128. Kennedy J.W., Ritchie J.L., Davis K.B., Stadius M.L., Maynard C., Fritz J.K. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med 1985;312:1073—8.

129. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932—6.

130. Califf R.M., O'Neil W., Stack R.S., Aronson L., Mark D.B., Mantell S., et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med 1988;108:658—62.

131. Shah P.K., Cercek B., Lew A.S., Ganz W. Angiographic validation of bedside markers of reperfusion. J Am Coll Cardiol 1993;21:55—61.

132. Schroder R., Dissmann R., Bruggemann T., Wegscheider K., Linderer T., Tebbe U., et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994;24:384—91.

133. Saran R.K., Been M., Furniss S.S., Hawkins T., Reid D.S. Reduction in ST segment elevation after thrombolysis predicts either coronary reperfusion or preservation of left ventricular function. Br Heart J 1990;64:113—7.

134. Richardson S.G., Morton P., Murtagh J.G., Scott M.E., O'Keeffe D.B. Relation of coronary arterial patency and left ventricular function to electrocardiographic changes after streptokinase treatment during acute myocardial infarction. Am J Cardiol 1988;61:961—5.

135. Hogg K.J., Hornung R.S., Howie C.A., Hockings N., Dunn F.G., Hillis W.S. Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a noninvasive marker. Br Heart J 1988;60:275—80.

136. Barbash G.I., Roth A., Hod H., Miller H.I., Rath S., Har-Zahav Y., et al. Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction. Br Heart J 1990;64:241—7.

137. Bossaert L., Conraads V., Pintens H. ST-segment analysis: a useful marker for reperfusion after thrombolysis with APSAC? The Belgian EMS Study Group. Eur Heart J 1991;12:357—62.

138. Krucoff M.W., Croll M.A., Pope J.E., Granger C.B., O'Connor C.M., Sigmon K.N., et al. Continuous 12-lead ST segment recovery analysis in the TAMI 7 Study: performance of a noninvasive method for real time detection of failed myocardial reperfusion. Circulation 1993;88:437—46.

139. Zabel M., Hohnloser S.H., Parussel A., Just H. ST segment analysis for assessment of coronary artery patency: comparison of surface ECG and Holter recordings. Eur Heart J 1992;13:1619—25.

140. Topol E.J., O'Neill W.W., Langburd A.B., Walton J.A. Jr., Bourdillon P.D., Bates E.R., et al. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction. Circulation 1987;75: 420—8.

141. Simoons M.L., Arnold A.E., Betriu A., de Bono D.P., Col J., Dougherty F.C., et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197—203.

142. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. BMJ 1991;302:555—60.

143. Abbottsmith C.W., Topol E.J., George B.S., Stack R.S., Kereiakes D.J., Candela R.J., et al. Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. J Am Coll Cardiol 1990;16:770—8.

144. White H.D., Cross D.B., Williams B.F., Norris R.M. Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. Br Heart J 1990;64:177—81.

145. Barbash G.I., Hod H., Roth A., Faibel H.E., Mandel Y., Miller H.I., et al. Repeat infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. J Am Coll Cardiol 1990;16:779—83.

146. Simoons M.L., Arnout J., van den Brand M., Nyssen K., Verstraete M. Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group. Am J Cardiol 1993;71:524—8.

147. Ellis S.G., da Silva E.R., Heyndrickx G., Talley J.D., Cernigliaro C., Steg G., et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994;90:2280—4.

148. Puleo P.R., Meyer D., Wathen C., Tawa C.B., Wheeler S., Hamburg R.J., et al. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med 1994;331:561—6.

149. Lee T.H., Pearson S.D., Johnson P.A., Garcia Т.В., Weisberg M.C., Guadagnoli E., et al. Failure of information as an intervention to modify clinical management. A time-series trial in patients with acute chest pain. Ann Intern Med 1995;122:434—7.

150. Heidbuchel H., Tack J., Vanneste L., Ballet A., Ector H., Van de Werf F. Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardic agent on their incidence. Circulation 1994;89:1051—9.

151. Capone R.J., Pawitan Y., el-Sherif N., Geraci T.S., Handshaw K., Morganroth J., et al. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol 1991; 18:1434—8.

152. Mark D.B., Sigmon K., Topol E.J., Kereiakes D.J., Pryor D.B., Candela R.J., et al. Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. Circulation 1991;83:1186—93.

153. Newby L.K., Califf R.M., Guerci A., Weaver W.D., Col J., Horgan J.H., et al. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. J Am Coll Cardiol 1996;27:625—32.

154. Moss A.J. Prognosis after myocardial infarction. Am J Cardiol 1983;52:667—9.

155. Gottlieb S., Moss A.J., McDermott M., Eberly S. Interrelation of left ven-tricular ejection fraction, pulmonary congestion and outcome in acute myocardial infarction. Am J Cardiol 1992;69:977—84.

156. Nicod P., Gilpin E., Dittrich H., Chappuis F., Ahnve S., Engler R., et al. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol 1988;61:1165—71.

157. Gadsboll N., Hoilund-Carlsen P.F., Madsen E.B., Marving J., Pedersen A., Lonborg-Jensen H., et al. Right and left ventricular ejection fractions: relation to one-year prognosis in acute myocardial infarction. Eur Heart J 1987;8:1201—9.

158. Serruys P.W., Simoons M.L., Suryapranata H., Vermeer F., Wijns W., van den Brand M., et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986;7:729—42.

159. Taylor G.J., Humphries J.O., Mellits E.D., Pitt B., Schulze R.A., Griffith L.S., et al. Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction. Circulation 1980; 62:960—70.

160. White H.D., Norris R.M., Brown M.A., Takayama M., Maslowski A., Bass N.M., et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317:850—5.

161. Gunnar R.M., Bourdillon P.D., Dixon D.W., Fuster V., Karp R.B., Kennedy J.W., et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). Circulation 1990;82:664—707.

162. Bittl J.A. Indications, timing, and optimal technique for diagnostic angiography and angioplasty in acute myocardial infarction. Chest 1991;99(4 Suppl):150S-6S.

163. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation 1989;78:441—4.

164. Califf R.M., Granger C. TIMI IIB follow-up. Lessons for clinicians and investigators [Editorial]. Circulation 1992;85:839—41.

165. Kulick D.L., Rahimtoola S.H. Risk stratification in survivors of acute myocardial infarction: routine cardiac catheterization and angiography is a reasonable approach in most patients [Editorial]. Am Heart J 1991;121:641—56.

166. Wall T.C., Mark D.B., Califf R.M., Collins G., Burgess R., Skelton T.N., et al. Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study. Am J Cardiol 1989;63:423—8.

167. Kleiman N.S., Terrin M., Mueller H., Chaitman B., Roberts R., Knatterud G.L., et al. Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. J Am Coll Cardiol 1992;19:1129—35.

168. Muller D.W., Topol E.J., Ellis S.G., Woodlief L.H., Sigmon K.N., Kereiakes D.J., et al. Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group. J Am Coll Cardiol 1991;18:1594—601.

169. Eisenstein E.L., Newby L.K., Knight J.D., Shaw L.J., Califf R.M., Topol E.J., et al. Cost avoidance through early discharge of the uncomplicated acute myocardial infarction patient [Abstract]. J Am Coll Cardiol 1996;27:244A-5A.

170. Topol E.J., Burek K., O'Neill W.W., Kewman D.G., Kander N.H., Shea M.J., et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med 1988;318:1083—8.

171. Pryor D.B., Hindman M.C., Wagner G.S., Califf R.M., Rhoads M.K., Rosati R.A. Early discharge after acute myocardial infarction. Ann Intern Med 1983;99:528—38.

172. Goldman L., Cook E.F., Lee T.H., Rouan O.W., Weisberg M.C. Prospective validation of a simple algorithm to predict complications requiring intensive care among emergency room patients with acute chest pain [Abstract]. Clin Res 1989;37:524A.

173. Sanz G., Betriu A., Oller G., Matas M., Magrina J., Pare C., et al. Feasibility of early discharge after acute Q wave myocardial infarction in patients not receiving thrombolytic treatment. J Am Coll Cardiol 1993;22:1795—801.

174. Shaw L.J., Pieper K., Peterson E.D., Eagle K.A., Wagner G.S., Califf R.M. Optimization of resources by efficient use of readily available simple clinical measures in a high-risk post-myocardial infarction population. Presented at the 13th Annual Meeting of the Association for Health Service Research, Atlanta, GA, June 9-11, 1996.

175. Schreiber T., Marsalese D., Griffin J., Donohue B., Sampaolesi A., Con-stantini C., et al. Identification of ultra low-risk patients following primary angioplasty for acute myocardial infarction [Abstract]. J Am Coll Cardiol 1996;27:83A.

176. Peterson E.D., Jollis J.G., DeLong E.R., Stafford J.A., Muhlbaier L.H., Shaw L.J., et al. National patterns of post-MI noninvasive testing in the elderly: results in 190,237 patients [Abstract]. Circulation 1996;94:1—441.

177. Mark D.B., Granger C.B., Ellis S.G., Phillips H.R., Knight D., Davidson-Ray L., et al. Costs of direct angioplasty versus thrombolysis for acute myocardial infarction: results from the GUSTO II randomized trial [Abstract]. Circulation 1996;94:1—168.

178. Charles E.D., Rogers W.J., Reeder G.S., Chesebro J.H., Papapietro S.E. Economic advantages of a conservative strategy for AMI management: rt-PA without obligatory PTCA [Abstract]. J Am Coll Cardiol 1989;13:152A.

179. Mark D.B. Medical economics and health policy issues for interventional cardiology. In: Topol E.J., ed. Textbook of Interventional Cardiology, 2d ed. Philadelphia: WB Saunders; 1994;1323—53.

180. Risk stratification and survival after myocardial infarction. Multicenter Post-Infarction Research Group. N Engl J Med 1983;309:321—6.

181. Sanz G., Castaner A., Betriu A., Magrina J., Roig E., Coll S., et al. Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. N Engl J Med 1982;306:1065—70.

182. Harris P. The problem of defining heart failure. Cardiovasc Drugs Ther 1994;8:447—52.

183. Greenberg H., McMaster P., Dwyer E.M. Jr. Left ventricular dysfunction after acute myocardial infarction: results of a prospective multicenter study. J Am Coll Cardiol 1984;4:867—74.

184. Volpi A., De Vita C., Franzosi M.G., Geraci E., Maggioni A.P., Mauri F., et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardio (GISSI)-2 Data Base. Circulation 1993;88:416—29.

185. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J. Jr., Cuddy Т.Е., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669—77.

186. Konstam M.A., Kronenberg M.W., Rousseau M.F., Udelson J.E., Melin J., Stewart D., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993;88(5 Pt 1):2277—83.

187. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669—85.

188. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686—7.

189. Anderson W.D., Wagner N.B., Lee K.L., White R.D., Yuschak J., Behar V.S., et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. VI: Identification of screening criteria for non-acute myocardial infarcts. Am J Cardiol 1988;61:729—33.

190. Hamby R.I., Murphy D., Hoffman I. Clinical predictability of left ventricular function post myocardial infarction from the electrocardiogram. Am Heart J 1985;109:338—42.

191. Silver M.T., Rose G.A., Paul S.D., O'Donnell C.J., O'Gara P.T., Eagle K.A. A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Ann Intern Med 1994;121:750—6.

192. Corbett J.R., Dehmer G.J., Lewis S.E., Woodward W., Henderson E., Par-key R.W., et al. The prognostic value of submaximal exercise testing with radionuclide ventriculography before hospital discharge in patients with recent myocardial infarction. Circulation 1981;64:535—44.

193. White H.D., Norris R.M., Brown M.A., Brandt P.W., Whitlock R.M., Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44—51.

194. Bouwels L., Hertzberger D. How long should high-risk patients with acute anterior wall myocardial infarction be monitored? Int J Cardiol 1992;35:355—64.

195. McComb J.M., Gold H.K., Leinbach R.C., Newell J.B., Ruskin J.N., Garan H. Electrically induced ventricular arrhythmias in acute myocardial infarction treated with thrombolytic agents. Am J Cardiol 1988;62:186—91.

196. Kuchar D.L., Thorburn C.W., Sammel N.L. Late potentials detected after myocardial infarction: natural history and prognostic significance. Circulation 1986;74:1280—9.

197. Willems A.R., Tijssen J.G., van Capelle F.J., Kingma J.H., Hauer R.N., Vermeulen F.E., et al. Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction. The Dutch Ventricular Tachycardia Study Group of the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol 1990;16:521—30.

198. Pedretti R., Etro M.D., Laporta A., Braga S.S., Caru B. Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. Am J Cardiol 1993;71:1131—41.

199. Vaage-Nilsen M., Rasmussen V., Hansen J.F., Hagerup L., Sorensen M.B., Bjergaard O.P., et al. Effect of verapamil on ischemia and ventricular arrhythmias after an acute myocardial infarction: prognostic implications. The Danish Verapamil In farction Trial II Study Group. J Cardiovasc Pharmacol. 1991;18:S26—9.

200. Maggioni A.P., Zuanetti G., Franzosi M.G., Rovelli F., Santoro E., Stas-zewsky L., et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993;87:312—22.

201. Bigger J.T. Jr., Fleiss J.L., Rolnitzky L.M. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous elec-trocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986;58:1151—60.

202. Kostis J.B., Byington R., Friedman L.M., Goldstein S., Furberg C. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. J Am Coll Cardiol 1987:10:231—42.

203. Zhang Y.Z., Wang S.W., Hu D.Y., Zhu G.Y. Prediction of life-threatening arrhythmia in patients after myocardial infarction by late potentials, ejection fraction and Holter monitoring. Jpn Heart J 1992;33:15—23.

204. Candell-Riera J., Permanyer-Miralda G., Castell J., Rius-Davi A., Domingo E., Alvarez-Aunon E., et al. Uncomplicated first myocardial infarction: strategy for comprehensive prognostic studies. J Am Coll Cardiol 1991;18:1207—19.

205. Currie P., Saltissi S. Transient myocardial ischaemia after acute myocardial infarction does not induce ventricular arrhythmias. Br Heart J 1993;69:303—7.

206. Connolly S.J., Cairns J.A. Prevalence and predictors of ventricular premature complexes in survivors of acute myocardial infarction. CAMIAT Pilot Study Group. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Am J Cardiol 1992;69:408—11.

207. Eldar M., Sievner Z., Goldbourt U., Reicher-Reiss H., Kaplinsky E., Behar S. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. The SPRINT Study Group. Ann Intern Med 1992; 117:31—6.

208. Behar S., Rabinowitz В., Zion M., Reicher-Reiss H., Kaplinsky E., Abi-nader E., et al. Immediate and long-term prognostic significance of a first anterior versus first inferior wall Q-wave acute myocardial infarction. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group. Am J Cardiol 1993;72:1366—70.

209. McClements B.M., Adgey A.A. Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era. J Am Coll Cardiol 1993;21:1419—27.

210. Steinberg J.S., Regan A., Sciacca R.R., Bigger J.T. Jr., Fleiss J.L. Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram. Am J Cardiol 1992;69:13—21.

211. Willems J.L., Willems R.J., Willems G.M., Arnold A.E., Van de Werf F., Verstraete M. Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Circulation 1990;82:1147—58.

212. Kowey P.R., Friehling T., Meister S.G., Engel T.R. Late induction of tachycardia in patients with ventricular fibrillation associated with acute myocardial infarction. J Am Coll Cardiol 1984;3:690—5.

213. van Hemel N.M., Kingma J.H., Defauw J.A., Vermeulen F.E., Mast E.G., Ernst J.M., et al. Left ventricular segmental wall motion score as a criterion for selecting patients for direct surgery in the treatment of postinfarction ventricular tachycardia. Eur Heart J 1989;10:304—15.

214. Aguirre F.V., Kern M.J., Hsia J., Serota H., Janosik D., Greenwalt T., et al. Importance of myocardial infarct artery patency on the prevalence of ventricular arrhythmia and late potentials after thrombolysis in acute myocardial infarction. Am J Cardiol 1991;68:1410—6.

215. Hong M., Peter T., Peters W., Wang F.Z., Xiu Y.X., Vaughn C., et al. Relation between acute ventricular arrhythmias, ventricular late potentials and mortality in acute myocardial infarction. Am J Cardiol 1991;68:1403—9.

216. Denes P., el-Sherif N., Katz R., Capone R., Carlson M., Mitchell L.B., et al. Prognostic significance of signal-averaged electrocardiogram after thrombolytic therapy and/or angioplasty during acute myocardial infarction (CAST substudy). Cardiac Arrhythmia Suppression Trial (CAST) SAECG Substudy Investigators. Am J Cardiol 1994;74:216—20.

217. Gomes J.A., Winters S.L., Stewart D., Horowitz S., Milner M., Barreca P. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring.
J Am Coll Cardiol 1987;10:349—57.

218. Hohnloser S.H., Franck P., Klingenheben T., Zabel M., Just H. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era. A prospective trial. Circulation 1994;90:1747—56.

219. Zaman A.G., Morris J.L., Smyllie J.H., Cowan J.C. Late potentials and ventricular enlargement after myocardial infarction. A new role for high-resolution electrocardiography? Circulation 1993;88:905—14.

220. Kleiger R.E., Miller J.P., Bigger J.T. Jr., Moss A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59: 256—62.

221. Farrell T.G., Odemuyiwa O., Bashir Y., Cripps T.R., Malik M., Ward D.E., et al. Prognostic value of baroreflex sensitivity testing after acute myocardial infarction. Br Heart J 1992; 67: 129—37.

222. La Rovere M.T., Mortara A., Specchia G., Schwartz P.J. Myocardial infarction and baroreflex sensitivity. Clinical studies. G Ital Cardiol 1992;22:639—45.

223. Rich M.W., Saini J.S., Kleiger R.E., Carney R.M., teVelde A., Freedland K.E. Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography. Am J Cardiol 1988;62(10 Pt 1):714—7.

224. Zbilut J.P., Lawson L. Decreased heart rate variability in significant cardiac events. Crit Care Med 1988;16:64—6.

225. Schwartz P.J., La Rovere M.T., Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for postmyocardial infarction risk stratification. Circulation 1992;85(1 Suppl):177—91.

226. Zabel M., Klingenheben T., Hohnloser S.H. Changes in autonomic tone following thrombolytic therapy for acute myocardial infarction: assessment by analysis of heart rate variability. J Cardiovasc Electrophysiol 1994;5:211—8.

227. Singh N., Mironov D., Armstrong P.W., Ross A.M., Langer A. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. Circulation 1996; 93: 1388—95.

228. Hamer A., Vohra J., Hunt D., Sloman G. Prediction of sudden death by electrophysiologic studies in high risk patients surviving acute myocardial infarction. Am J Cardiol 1989;50:223—9.

229. Marchlinski F.E., Buxton A.E., Waxton H.L., Josephson M.E. Identifying patients at risk of sudden death after myocardial infarction: value of the response to programmed stimulation, degree of ventricular ectopic activity and severity of left ventricular dysfunction. Am J Cardiol 1983;52:1190—6.

230. Richards D.A., Byth K., Ross D.L., Uther J.B. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction? Circulation 1991;83:756—63.

231. Santarelli P., Bellocci F., Loperfido F., Mazzari M., Mongiardo R., Montenero A.S., et al. Ventricular arrhythmia induced by programmed ventricular stimulation after acute myocardial infarction. Am J Cardiol 1985;55:391—4.

232. Roy D., Marchand E., Theroux P., Waters D.D., Pelletier G.B., Bourassa M.G. Programmed ventricular stimulation in survivors of an acute myocardial infarction. Circulation 1985;72: 487—94.

233. Waspe L.E., Seinfeld D., Ferrick A., Kim S.G., Matos J.A., Fisher J.D. Prediction of sudden death and spontaneous ventricular tachycardia in survivors of complicated myocardial infarction: value of the response to programmed stimulation using a maximum of three ventricular extrastimuli. J Am Coll Cardiol 1985;5:1292—301.

234. Gonzalez R., Arriagada D., Corbalan R., Chamorro G., Fajuri A., Rodriguez J.A. Role of programmed electrical stimulation of the heart in risk stratification post-myocardial infarction. Pacing Clin Electrophysiol 1988;11: 283—8.

235. Denniss A.R., Baaijens H., Cody D.V., Richards D.A., Russell P.A., Young A.A., et al. Value of programmed stimulation and exercise testing in predicting one-year mortality after acute myocardial infarction. Am J Cardiol 1985;56:213—20.

236. Denniss A.R., Richards D.A., Cody D.V., Russell P.A., Young A.A., Cooper M.J., et al. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 1986;74:731—45.

237. Cripps T., Bennett E.D., Camm A.J., Ward D.E. Inducibility of sustained monomorphic ventricular tachycardia as a prognostic indicator in survivors of recent myocardial infarction: a prospective evaluation in relation to other prognostic variables. J Am Coll Cardiol 1989;14:289—96.

238. Bhandari A.K., Hong R., Kotlewski A., Mclntosh N., Au P., Sankoorikal A., et al. Prognostic significance of programmed ventricular stimulation in survivors of acute myocardial infarction. Br Heart J 1989;61:410—6.

239. Richards D.A., Cody D.V., Denniss A.R., Russell P.A., Young A.A. Uther J.B. Ventricular electrical instability: a predictor of death after myocardial infarction. Am J Cardiol 1983;51:75—80.

240. Krone R.J., Friedman E., Thanavaro S., Miller J.P., Kleiger R.E., Oliver G.C. Long-term prognosis after first Q-wave (transmural) or non-Q-wave (non-transmural) myocardial infarction: analysis of 593 patients. Am J Cardiol 1983;52:234—9.

241. Klein J., Froelicher V.F., Detrano R., Dubach P., Yen R. Does the rest electrocardiogram after myocardial infarction determine the predictive value of exercise-induced ST depression? A 2 year follow-up study in a veteran population. J Am Coll Cardiol 1989;14:305—11.

242. Sutton J.M., Topol E.J. Significance of a negative exercise thallium test in the presence of a critical residual stenosis after thrombolysis for acute myocardial infarction. Circulation 1991;83:1278—86.

243. Mahmarian J.J., Pratt C.M., Boyce T.M., Verani M.S. The variable extent of jeopardized myocardium in patients with single vessel coronary artery disease: quantification by thallium-201 single photon emission computed tomography. J Am Coll Cardiol 1991;17:355—62.

244. Patterson R.E., Horowitz S.F., Eng C., Meller J., Goldsmith S.J., Pichard A.D., et al. Can noninvasive exercise test criteria identify patients with left main or 3-vessel coronary disease after a first myocardial infarction? Am J Cardiol 1983;51:361—72.

245. Pirelli S., Inglese E., Suppa M., Corrada E., Campolo L. Dipyridamole-thallium 201 scintigraphy in the early post-infarction period. (Safety and accuracy in predicting the extent of coronary disease and future recurrence of angina in patients suffering from their first myocardial infarction). Eur Heart J 1988;9:1324—31.

246. Valette H., Bourguignon M.H., Le Guludec D., Merlet P., Dove P.J., Kiger J.P., et al. ECG gated thallium 201 myocardial images: value in detecting multivessel disease in patients on anti anginal therapy 1-3 months after myocardial infarction. Eur J Nucl Med 1988:13:551—6.

247. Smeets J.P., Rigo P., Legrand V., Chevigne M., Hastir F., Kulbertus H.E. Prognostic value of thallium-201 stress myocardial scintigraphy with exercise ECG after myocardial infarction. Cardiology 1981;68(Suppl 2):67—70.

248. Gibson R.S., Watson D.D., Craddock G.B., Crampton R.S., Kaiser D.L., Denny M.J., et al. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation 1983;68:321—36.

249. Gibson R.S., Beller G.A., Gheorghiade M., Nygaard T.W., Watson D.D., Huey B.L., et al. The prevalence and clinical significance of residual myocardial ischemia 2 weeks after uncomplicated non-Q wave infarction: a prospective natural history study. Circulation 1986;73:1186—98.

250. Griffin B.P., Shah P.K., Diamond G.A., Berman D.S., Ferguson J.G. Incremental prognostic accuracy of clinical, radionuclide and hemodynamic data in acute myocardial infarction. Am J Cardiol 1991;68:707—12.

251. Nicod P., Corbett J.R., Firth B.G., Lewis S.E., Rude R.E., Huxley R., et al. Prognostic value of resting and submaximal exercise radionuclide ventriculography after acute myocardial infarction in high-risk patients with single and multivessel disease. Am J Cardiol 1983;52:30—6.

252. Michels K.B., Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995;91:476—85.

253. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89:1545—56.

254. Mark D.B., Naylor C.D., Hlatky M.A., Califf R.M., Topol E.J., Granger C.B., et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med 1994;331:1130—5.

255. Yusuf S., Zucker D., Peduzzi P., Fisher L.D., Takaro T., Kennedy J.W., et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563—70,

256. Mark D.B., Nelson C.L.. Califf R.M., Harrell F.E. Jr., Lee K.L., Jones R.H., et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994;89:2015—25.

257. Califf R.M., Harrell F.E. Jr., Lee K.L., Rankin J.S., Hlatky M.A., Mark D.B., et al. The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. JAMA 1989;261:2077—86.

258. Siegel D., Grady D., Browner W.S., Hulley S.B. Risk factor modification after myocardial infarction. Ann Intern Med 1988;109:213—8.

259. Yusuf S., Lessem J., Jha P., Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens Suppl 1993;11:S61—73.

260. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383—9.

261. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015—23.

262. American Heart Association. Heart and Stroke Facts. Dallas: American Heart Assoc; 1994.

263. Krumholz H.M., Cohen B.J., Tsevat J., Pasternak R.C., Weinstein M.C. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993;22:1697—702.

264. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533—7.

265. Meade T.W., Wilkes H.C., Stirling Y., Brennan P.J., Kelleher C., Browne W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J 1988;9:836—43.

266. Grady D., Rubin S.M., Petitti D.B., Fox C.S., Black D., Ettinger B., et al. Hormone the

20.11.2008 | Какие сахароснижающие препараты лучше?

19.11.2008 | Розувастатин при ХСН ничего не меняет.

18.11.2008 | Догоспитальный тромболизис снижает летальность

16.11.2008 | Омега-3 полиненасыщенные жирные кислоты при ХСН

14.11.2008 | Сон должен быть достаточным.

12.11.2008 | Наушники могут нарушать работу кардиостимуляторов

10.11.2008 | Новая система допуска врачей к оказанию медпомощи.